PNC-27 5mg

Description

PNC-27 Technical Overview

PNC-27 is a synthetic experimental peptide designed to investigate molecular interactions involving the p53 tumor suppressor protein and HDM2. The compound combines a p53-derived HDM2-binding region with a membrane-associated peptide segment.

PNC-27 has been studied in experimental oncology models examining plasma membrane integrity, cellular viability, and the localization of HDM2 in malignant cells.

Preclinical studies have described interactions between PNC-27 and membrane-associated HDM2, followed by membrane disruption in selected cellular systems. These observations remain experimental and do not establish clinical effectiveness.

Compound Specifications

Storage and Handling

• Follow the manufacturer’s recommended stability conditions.
• Protect the material from moisture, light, and contamination.
• Minimize unnecessary temperature changes during laboratory storage.
• Handle using procedures appropriate for experimental cytotoxic materials.

Lyophilized Format

PNC-27 can be prepared in lyophilized form for experimental research. The physical state and storage requirements of this particular product must be verified using manufacturer documentation.

Research Use Disclaimer

PNC-27 is not FDA-approved for cancer treatment or any other therapeutic application. The material is described exclusively for laboratory investigation and is not intended for human or veterinary administration.

Frequently Asked Questions

What Is PNC-27 5mg?

PNC-27 5mg is an experimental peptide preparation designed for investigations of p53-derived sequences and HDM2-associated membrane interactions.

What Molecular Target Is Associated With PNC-27?

Published research has focused on HDM2 associated with the plasma membrane in selected cancer cell models.

What Is the Difference Between PNC-27 and PNC-28?

They are distinct research peptides incorporating different p53-derived regions.

What Research Areas Involve PNC-27?

PNC-27 is investigated in membrane biology, experimental oncology, molecular interaction research, and peptide engineering.

Is PNC-27 FDA-Approved?

No. It is not an FDA-approved therapeutic compound.

Research Overview

PNC-27 research originated from investigations into synthetic peptides derived from the p53 tumor suppressor protein.

Experimental findings suggested that a peptide combining an HDM2-binding sequence with a membrane-associated region could influence membrane integrity in selected malignant cell models.

p53 and HDM2 Research

The interaction between p53 and HDM2 is important in the regulation of cellular stress responses. PNC-27 was designed to investigate a specific aspect of this protein-binding system.

Membrane Integrity Research

Laboratory experiments have reported changes in membrane permeability and pore formation following PNC-27 exposure.

Experimental Cellular Responses

Researchers have examined cell viability and membrane-associated changes in selected malignant cell lines. Observed responses cannot be assumed to apply to every cancer type.

Research Applications

References

1. PNC-27 and HDM2 Interaction Research. PubMed PMID: 20080680.
2. PNC-27 Experimental Research. Biomedicines, 2022, 10(5), 945.

Certificate of Analysis (COA)

Researchers should verify peptide identity, sequence, purity, and compound content using batch-specific analytical documentation.

For available product information, contact Peptide Lives.